Search results for "AGENTS"

showing 10 items of 7330 documents

Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk

2017

BACKGROUND In patients with chronic hepatitis C infection, a sustained virologic response (SVR) to interferon-based therapy markedly decreases the incidence of hepatocellular carcinoma (HCC) over the long term. This is also true for patients who have hepatic cirrhosis, as well as for those with HCC-with or without cirrhosis-who have undergone resection or ablation with curative intent. Recent publications, however, have reported a higher incidence of HCC among patients in both of these subgroups who were treated with direct antiviral agents (DAA) rather than interferon-based therapy. METHODS A selective search for pertinent literature was carried out in the PubMed database with the search t…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisHepatitis C virusReview Articlemedicine.disease_causeAntiviral AgentsGastroenterology03 medical and health sciencesDrug treatment0302 clinical medicineChronic hepatitisRisk FactorsInterferonInternal medicinemedicineHumansbusiness.industryIncidence (epidemiology)Liver NeoplasmsGeneral MedicineHepatitis C Chronicmedicine.diseasedigestive system diseasesTumor progression030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusinessmedicine.drugDeutsches Ärzteblatt international
researchProduct

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

2011

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in th…

medicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsPolymorphism Single NucleotideFlaviviridaeInternal medicineGenotypeEpidemiologyRibavirinmedicineHumansClinical Trials as TopicHepatologybiologybusiness.industryInterleukinsLiver Neoplasmsvirus diseasesHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsLiver TransplantationNatural historyHepatocellular carcinomaInterferon Type IPractice Guidelines as TopicHCVInterferonsbusiness
researchProduct

Feasibility and Diagnostic Impact of Fluorescence-Based Diagnostic Laparoscopy in Hepatocellular Carcinoma: A Case Report

2002

Fluorescence-based diagnostic techniques are an evolving field in the staging of hepatologic and gastroenterologic malignancies. The method aims at improved accuracy in the detection of locoregional and distant metastases. In hepatocellular carcinoma, detection of metastases is of utmost importance, because advanced tumors preclude curative surgical therapy. We present here our first experience of fluorescence-based diagnostic laparoscopy in a patient with hepatocellular carcinoma. We performed diagnostic laparoscopy in a 76-year-old woman who presented with a tumor of the liver and increased serum levels of alpha-fetoprotein. For photosensitization, 5-aminolevulinic acid (20 mg/kg bodyweig…

medicine.medical_specialtyCarcinoma HepatocellularLightDiagnostic laparoscopyFluorescenceMetastasisLight sourceHumansMedicineNeoplasm MetastasisLaparoscopyAgedNeoplasm StagingHistological examinationPhotosensitizing Agentsmedicine.diagnostic_testbusiness.industryLiver NeoplasmsGastroenterologyAminolevulinic Acidmedicine.diseaseEndoscopySurgeryTransplantationHepatocellular carcinomaFemaleLaparoscopyRadiologybusinessEndoscopy
researchProduct

Dofetilide effects on the inhibition by trains of subthreshold conditioning stimuli.

2004

We investigated the electrophysiological actions of dofetilide upon the ventricular myocardium to determine whether the drug modifies the inhibitory effects of subthreshold stimuli trains upon ventricular refractoriness. In nine Langendorff perfused rabbit hearts, ventricular epicardial electrodes were used to determine the following parameters at baseline and during dofetilide perfusion (0.5 micromolar): effective (ERP) and functional (FRP) refractory periods, conduction velocity (CV), wavelength (WL), and ERP prolongation (inhibitory effect) induced by subthreshold stimuli trains (STr) at pulse frequencies of 100, 300, and 600 Hz. Dofetilide significantly prolongs ventricular refractorine…

medicine.medical_specialtyCardiac Complexes PrematureRefractory Period ElectrophysiologicalHeart VentriclesDofetilideStimulationInhibitory postsynaptic potentialNerve conduction velocityElectrocardiographyHeart Conduction SystemInternal medicinePhenethylaminesmedicinePotassium Channel BlockersAnimalsSulfonamidesDose-Response Relationship DrugSubthreshold conductionPulse (signal processing)business.industryCardiac Pacing ArtificialGeneral MedicineElectric StimulationElectrophysiologyAnesthesiaModels AnimalCardiologyRabbitsCardiology and Cardiovascular MedicinebusinessPerfusionAnti-Arrhythmia Agentsmedicine.drugPacing and clinical electrophysiology : PACE
researchProduct

ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission in…

2019

Treatment of vasculitides associated with anti-neutrophil cytoplasm antibodies (ANCA) (AAVs) has evolved dramatically in recent years, particularly since the demonstration of rituximab efficacy as remission induction and maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. In 2013, the French Vasculitis Study Group (FVSG) published recommendations for its use by clinicians. Since then, new data have made it possible to better specify and codify prescription of rituximab to treat AAVs. Herein, the FVSG Recommendations Committee, an expert panel comprised of physicians with extensive experience in the treatment and management of vasculitides, presents its con…

medicine.medical_specialtyCardiologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMaintenance Chemotherapy03 medical and health sciencesRemission induction0302 clinical medicineMaintenance therapymedicineHumans030212 general & internal medicineMedical prescriptionIntensive care medicineSocieties Medical030203 arthritis & rheumatologybusiness.industryRemission InductionGranulomatosis with PolyangiitisGeneral Medicinemedicine.diseaseBiological TherapyPractice Guidelines as TopicRituximabFranceGranulomatosis with polyangiitisbusinessMicroscopic polyangiitisVasculitisMepolizumabImmunosuppressive Agentsmedicine.drugLa Presse Médicale
researchProduct

Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish…

2020

Levosimendan is a new inodilator which involves 3 main mechanisms: increases the calcium sensitivity of cardiomyocytes, acts as a vasodilator due to the opening of potassium channels, and has a cardioprotective effect. Levosimendan is mainly used in the treatment of acute decompensated heart failure (class IIb recommendation according to the European Society of Cardiology guidelines). However, numerous clinical trials indicate the validity of repeated infusions of levosimendan in patients with stable heart failure as a bridge therapy to heart transplantation, and in patients with accompanying right ventricular heart failure and pulmonary hypertension. Due to the complex mechanism of action,…

medicine.medical_specialtyCardiotonic AgentsAcute decompensated heart failureinotropic agentsacute heart failuremedicine.medical_treatment030204 cardiovascular system & hematologylevosimendan03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansinodilatorAdverse effectExpert TestimonySimendanHeart FailureHeart transplantationbusiness.industryHydrazonesLevosimendanmedicine.diseasePulmonary hypertensionCardiac surgeryPyridazinesClinical trialHeart failurechronic advanced systolic heart failureCardiologyPolandCardiology and Cardiovascular Medicinebusinessmedicine.drugKardiologia Polska
researchProduct

Treatment of Tako-tsubo cardiomyopathy

2008

N.A.

medicine.medical_specialtyCardiotonic AgentsHeart diseasebusiness.industryCardiomyopathyTako-tsubo Cardiomyopathymedicine.diseaseTako-tsubo cardiomyopathyTakotsubo CardiomyopathyInternal medicinePractice Guidelines as TopicACE inhibitormedicineCardiologyHumansMyocardial diseaseCardiology and Cardiovascular MedicinebusinessBeta (finance)medicine.drugInternational Journal of Cardiology
researchProduct

Expert opinion on managing chronic HCV in patients with cardiovascular disease

2018

International audience; Extrahepatic manifestations of chronic HCV infection include cardiovascular diseases and an increase in cardiovascular mortality. The pathogenic mechanisms by which HCV contributes to cardiovascular disease are not well defined, however, it is likely that systemic inflammation, and the promotion of other metabolic diseases are involved. In this Review, the evidence for HCV infection as a non-traditional risk factor for cardiovascular disease is evaluated. Furthermore, practical advice to evaluate cardiovascular disease risk and disease in chronic hepatitis C patients are included for help in daily clinical practice. Despite the advances in therapies for the treatment…

medicine.medical_specialtyCardiotonic AgentsHepacivirusDisease030204 cardiovascular system & hematologySystemic inflammationAntiviral Agents03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesOdds RatioHumansMedicineDrug InteractionsPharmacology (medical)In patient030212 general & internal medicineRisk factorIntensive care medicineExpert TestimonyCardiovascular mortalityInflammationPharmacologybusiness.industryDisease progressionDisease ManagementHepatitis C Chronic3. Good healthInfectious DiseasesCardiovascular DiseasesExpert opinionPractice Guidelines as TopicDisease riskmedicine.symptombusiness
researchProduct

A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin

2013

Ghrelin is a peptide hormone produced mainly in the stomach that has widespread tissue distribution and diverse hormonal, metabolic and cardiovascular activities. The circulating ghrelin concentration increases during fasting and decreases after food intake. Ghrelin secretion may thus be initiated by food intake and is possibly controlled by nutritional factors. Lean subjects have increased levels of circulating ghrelin compared with obese subjects. Recent reports show that low plasma ghrelin is associated with elevated fasting insulin levels, insulin resistance and type 2 diabetes mellitus. Factors involved in the regulation of ghrelin secretion have not yet been defined; however, it is as…

medicine.medical_specialtyCardiotonic AgentsHyperlipidemias030209 endocrinology & metabolismPeptide hormoneBiologyCardiovascular System03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusInsulin SecretionDrug DiscoverymedicineAnimalsHumansHypoglycemic AgentsInsulinAntiatherogenic agentHypolipidemic Agents030304 developmental biology2. Zero hungerPharmacology0303 health sciencesEvidence-Based Medicinedigestive oral and skin physiologyType 2 Diabetes MellitusLipid Metabolismmedicine.diseaseGhrelin3. Good healthEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesGastric MucosaHyperglycemiaGhrelinhormones hormone substitutes and hormone antagonistsGhrelin secretionHormoneCurrent Pharmaceutical Design
researchProduct

Special Considerations for Antihypertensive Agents in Dialysis Patients

2010

Hypertension is present in most patients with end-stage renal disease and likely contributes to the premature cardiovascular disease in dialysis patients. Previous practice guidelines have recommended that, in patients on chronic dialysis, blood pressure (BP) should be reduced below 130/80 mm Hg. This is based on opinions but not strong evidence, since no concrete information exists about which BP values should be the parameter to follow and which should be the target BP values. The majority of the antihypertensive agents can be used in this population, but the pharmacokinetics altered by the impaired kidney function and dialyzability influence the appropriate dosage as well as the time and…

medicine.medical_specialtyCardiotonic AgentsHypertension RenalCombination therapyMetabolic Clearance Ratemedicine.drug_classVasodilator Agentsmedicine.medical_treatmentAdrenergic beta-AntagonistsPopulationAngiotensin-Converting Enzyme InhibitorsCardiotonic AgentsRenal DialysisInternal medicinemedicineHumansDrug InteractionsDiureticseducationAntihypertensive drugAntihypertensive AgentsDialysisRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryHematologyGeneral MedicineCalcium Channel Blockersmedicine.diseaseEndocrinologyBlood pressureCardiovascular DiseasesNephrologyPractice Guidelines as TopicPolypharmacyKidney Failure ChronicDrug Therapy CombinationHemodialysisbusinessAngiotensin II Type 1 Receptor BlockersKidney diseaseBlood Purification
researchProduct